A Phase 1 trial testing a Poseida Therapeutics cell therapy in men with prostate cancer is on hold after a patient enrolled in the study died of liver failure nearly three weeks after receiving the treatment.

The San Diego company, which has touted its product candidates as safer than early-generation versions developed by other companies, announced the FDA’s decision to pause the study on Monday.

Poseida (NASDAQ: PSTX) is evaluating P-PSMA-101, a chimeric antigen receptor T-cell (CAR-T) therapy, in patients with prostate cancer that has spread beyond its initial location and stopped responding to drugs intended to lower levels of… Read more »